Vertex Pharmaceuticals Incorporated
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$598.5M
Doctors Paid
10,033
Transactions
30,079
2024 Total
$107.1M
Payment Breakdown by Category
Research$533.2M (89.1%)
Royalty/License$41.0M (6.9%)
Consulting$16.4M (2.7%)
Travel$1.2M (0.2%)
Food & Beverage$473,514 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $533.2M | 7,562 | 89.1% |
| Royalty or License | $41.0M | 53 | 6.9% |
| Consulting Fee | $16.4M | 3,620 | 2.7% |
| Current or prospective ownership or investment interest | $2.6M | 6 | 0.4% |
| Grant | $2.2M | 59 | 0.4% |
| Travel and Lodging | $1.2M | 2,388 | 0.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.2M | 329 | 0.2% |
| Food and Beverage | $473,514 | 15,367 | 0.1% |
| Space rental or facility fees (teaching hospital only) | $155,100 | 108 | 0.0% |
| Education | $11,902 | 566 | 0.0% |
| Gift | $7,295 | 18 | 0.0% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $3,750 | 2 | 0.0% |
| Entertainment | $517.19 | 1 | 0.0% |
Payments by Type
Research
$533.2M
7,562 transactions
General
$65.3M
22,517 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy | $43.2M | 0 | 73 |
| Evaluation of Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty | $37.6M | 0 | 29 |
| A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease | $26.9M | 0 | 537 |
| A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease | $20.4M | 0 | 55 |
| A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy | $16.0M | 0 | 347 |
| A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis | $12.9M | 0 | 179 |
| A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of VX-548 in Subjects With Painful Lumbosacral Radiculopathy | $10.8M | 0 | 124 |
| A Single-arm Study to Evaluate Safety and Effectiveness of VX-548 for Acute Pain | $10.3M | 0 | 48 |
| A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for F508del and a Minimal Function Mutation (F/MF) | $10.3M | 0 | 259 |
| A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive CFTR Mutation and No F508del Mutation | $9.8M | 0 | 233 |
| A Phase 1/2 Study of the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) in Subjects With Transfusion-Dependent Beta-Thalassemia | $8.9M | 0 | 17 |
| A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Evaluating the Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy | $8.6M | 0 | 36 |
| Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN) | $8.6M | 0 | 112 |
| A Study Evaluating the Long-term Safety of VX-445 Combination Therapy | $8.4M | 0 | 246 |
| A Phase 1, First-in-human Study of Safety, Tolerability, and Pharmacokinetics of VX-634 | $7.8M | 0 | 20 |
| A Phase 3b Study to Evaluate Efficacy and Safety of a Single Dose of Autologous CRISPR Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects With Transfusion-Dependent Beta-Thalassemia or Severe Sickle Cell Disease | $7.1M | 0 | 10 |
| A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy | $7.1M | 0 | 214 |
| A Study of the Prevalance of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are of Recent African Ancestry or Geographic Origin | $6.5M | 0 | 485 |
| A Phase 1, First-in-human Study of Safety, Tolerability, and Pharmacokinetics of VX-828 | $6.5M | 0 | 2 |
| FIH HVs SAD, DDI, MAD, BA/FE cohort for new potentiator | $6.4M | 0 | 3 |
| A Phase 1, First-in-Human Study of Safety, Tolerability and Pharmacokinetics of VX-464 | $6.3M | 0 | 3 |
| A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-880 in Subjects Who Have Type 1 Diabetes Mellitus With Impaired Hypoglycemic Awareness and Severe Hypoglycemia | $6.0M | 0 | 31 |
| A Phase 1, First-in-human Study of Safety, Tolerability, and Pharmacokinetics of VX-668 | $6.0M | 0 | 7 |
| A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF) | $5.7M | 0 | 118 |
| A Dose-ranging Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy | $5.6M | 0 | 12 |
| A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF) | $5.5M | 0 | 114 |
| A Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy | $5.5M | 0 | 8 |
| A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis Who Have an F508del-CFTR Mutation | $4.7M | 0 | 217 |
| A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis | $4.1M | 0 | 54 |
| A Study Evaluating the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of VX-147 | $4.0M | 0 | 7 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| David Friedman, M.d, M.D | Nephrology | Boston, MA | $20.3M | $0 |
| Martin Pollak, Md, MD | Nephrology | Boston, MA | $20.3M | $0 |
| Prof. Alan Garber, M.d., Ph.d, M.D., PH.D | Internal Medicine | Cambridge, MA | $4.4M | $0 |
| Dr. Stanford Peng, Md, Phd, Facp, MD, PHD, FACP | Internal Medicine | Seattle, WA | $2.5M | $0 |
| Dr. Jason Gaglia, M.d, M.D | Endocrinology, Diabetes & Metabolism | Boston, MA | $2.4M | $0 |
| Jennifer Schneider, Md, MD | Hospitalist | Santa Rosa, CA | $555,857 | $0 |
| David Schwartz, M.d.(Mph), M.D.(MPH) | Pulmonary Disease | Aurora, CO | $471,115 | $0 |
| Cheryl Mensah, M.d, M.D | Hematology & Oncology | New Haven, CT | $222,250 | $0 |
| Dr. Leslie Kean, Md/Phd, MD/PHD | Pediatric Hematology-Oncology | Boston, MA | $212,621 | $0 |
| Jennifer Taylor-Cousar, M.d, M.D | Pediatrics | Denver, CO | $211,878 | $0 |
| Patrick Flume, Md, MD | Pulmonary Disease | Charleston, SC | $204,883 | $0 |
| Ugochi Ogu, M.d, M.D | Pediatrics | Memphis, TN | $195,390 | $0 |
| Gaurav Singal, M.d, M.D | Internal Medicine | Boston, MA | $180,000 | $0 |
| Glenn Chertow, Md, MD | Internal Medicine | Stanford, CA | $177,210 | $0 |
| Piotr Witkowski | Transplant Surgery | Chicago, IL | $156,964 | $0 |
| Dr. Haydar Frangoul, Md, MD | Pediatric Hematology-Oncology | Nashville, TN | $142,771 | $0 |
| Rajiv Agarwal, M.d, M.D | Nephrology | Indianapolis, IN | $128,190 | $0 |
| Dr. Jared Ament, M.d., M.p.h, M.D., M.P.H | Neurological Surgery | West Hills, CA | $126,662 | $0 |
| Carlos Milla, Md, MD | Pediatrics | Palo Alto, CA | $123,640 | $0 |
| Dr. Stuart Apfel, Md, MD | Neurology | West Hempstead, NY | $114,368 | $0 |
| Manu Jain, Md, MD | Pulmonary Disease | Chicago, IL | $105,485 | $0 |
| Gregory Sawicki, M.d, M.D | Pediatric Pulmonology | Boston, MA | $98,413 | $0 |
| Bonnie Ramsey | Pediatric Pulmonology | Seattle, WA | $97,364 | $0 |
| Stephan Grupp, M.d, M.D | Pediatrics | Philadelphia, PA | $96,002 | $0 |
| Richard Kolchin, Md, MD | Allergy & Immunology | Brooklyn, NY | $89,793 | $0 |
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated has made $598.5M in payments to 10,033 healthcare providers, recorded across 30,079 transactions in the CMS Open Payments database. In 2024, the company paid $107.1M. The top product by payment volume is KALYDECO ($21.8M).
Payments were distributed across 200 medical specialties. The top specialty by payment amount is Nephrology ($41.1M to 142 doctors).
Payment categories include: Food & Beverage ($473,514), Consulting ($16.4M), Research ($533.2M), Travel & Lodging ($1.2M), Royalties ($41.0M).
Vertex Pharmaceuticals Incorporated is associated with 6 products in the CMS Open Payments database, including KALYDECO, ORKAMBI, and SYMDEKO.